the aimi trial l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
The AiMI Trial PowerPoint Presentation
Download Presentation
The AiMI Trial

Loading in 2 Seconds...

play fullscreen
1 / 9

The AiMI Trial - PowerPoint PPT Presentation


  • 97 Views
  • Uploaded on

AngioJet in Acute Myocardial Infarction Trial. The AiMI Trial.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'The AiMI Trial' - rance


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
the aimi trial

AngioJet in Acute Myocardial Infarction Trial

The AiMI Trial

Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD, Michael Azrin, MD, Dwight Stapleton, MD, Cindy Setum, PHD, Jeffrey Popma, MD, for the AIMI Investigators

The Journal of The American College of Cardiology

aimi trial background
AiMI Trial: Background
  • AiMI was a multicenter, prospective randomized two-arm trial comparing AngioJet thrombectomy followed by definitive treatment (angioplasty, stent and eptifibatide), versus immediate definitive treatment only, in patients undergoing intervention for acute myocardial infarction.
  • The hypothesis was that rheolytic thrombectomy with the Possis Angiojet catheter prior to definitive therapy for acute myocardial infarction would reduce infarct size compared with immediate definitive therapy.

J Am Coll Cardiol 2006;48:244–52

aimi trial study design
AiMI Trial: Study Design

Transmural anterior MI or large inferior MI, with definitive treatment being initiated within 12 hours of symptom onset. Treated vessels were native coronary arteries ≥ 2mm in diameter. Angiographic evidence of thrombus was not required for patient enrollment.

Randomized.

25% female, mean age 60 years, mean follow-up 30 days

95% received Eptifibatide

Primary PCI Control

n=240

Rheolytic Thrombectomy using the Possis Angiojet XMI device

n=240

  • Primary Endpoint: Final infarct size at 14-28 days, as measured by Tc-99m sestamibi SPECT imaging
  • Secondary Endpoint: ST segment resolution, post-procedure TIMI flow, corrected TIMI frame count, TIMI myocardial perfusion grade, MACE (death, new Q wave MI, stroke, target lesion revascularization), ejection fraction and procedural complications

J Am Coll Cardiol 2006;48:244–52

aimi trial primary endpoint
AiMI Trial: Primary Endpoint

Primary Endpoint of Infarct Size

p=0.03

  • As measured by nuclear scan, the 197 intent-to-treat patients in the AngioJet arm had a larger final infarct size than the 205 patients in the control arm (12.5% +/- 12.1 v. 9.8% +/- 10.9; p=0.03).

12.5%

9.8%

Angiojet

Primary PCI

n=197

n=205

J Am Coll Cardiol 2006;48:244–52

aimi trial secondary endpoint
AiMI Trial: Secondary Endpoint

Rate of MACE in Patients Undergoing Throbectomy

p=0.01

  • The rate of MACE was higher in patients undergoing thrombectomy (6.7% v. 1.7%; p=0.01).

J Am Coll Cardiol 2006;48:244–52

aimi trial mortality
AiMI Trial: Mortality

Rate of Mortality in Patients Undergoing Throbectomy

p=0.01

  • Mortality rates at 30 days were higher in those undergoing thrombectomy (4.6% (n=11) v. 0.8% (n=2); p=0.01).

J Am Coll Cardiol 2006;48:244–52

aimi trial secondary endpoint7
AiMI Trial: Secondary Endpoint

Rate of TIMI 3 Flow

p<0.02

  • The rates of TIMI 3 flow after completion of the procedure was lower in those randomized to thrombectomy (92% thrombectomy v. 97% control, p<0.02).
  • For all of the remaining secondary endpoints, there were no statistically significant difference between the two treatment arms.

J Am Coll Cardiol 2006;48:244–52

aimi trial limitations
AiMI Trial: Limitations
  • “Randomization that occurred after angiography may have introduced selection bias against enrolling high-risk patients with a large amount of angiographically apparent thrombus. No data is available to confirm such bias in enrollment.”
  • “Another limitation is that MI size rather than myocardial salvage was measured. As a result, the effect of a lower baseline TIMI flow grade in patients treated with adjunct RT cannot be determined.”
  • “It is difficult to ascertain whether the higher baseline TIMI flow grades contributed to the very favorable outcomes in patients treated with PCI alone.”

J Am Coll Cardiol 2006;48:244–52

aimi trial summary
AiMI Trial: Summary
  • Among patients with ST elevation MI, infarct size and mortality rates significantly increased among patients treated with rheolytic thrombectomy compared with the primary PCI control arm.
  • These results do not support the routine use of rheolytic thrombectomy in ST segment elevation MI.

J Am Coll Cardiol 2006;48:244–52